Topiramate And Phentermine

Overview

4.7 out of 5 (10 Reviews)

Credits

1.25

Post Assessment Questions

8

Expiration Date

31 Dec 2023

Last Reviewed

1 Jan 2021

Estimated Time To Finish

75 Minutes

Stay up to date on the latest medical knowledge

Start This Activity
 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Phentermine and extended-release (ER) topiramate have been used separately in various ways. Phentermine was first introduced in 1959 as part of an anti-obesity combination drug. Topiramate was released for commercial use in 1996. Phentermine on its own has been used for short-term treatment of obesity in combination with exercise and caloric restriction. In addition, Topiramate has been used to treat partial-onset or primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and as a prophylactic treatment of migraine headaches. The United States Food and Drug Administration approved the combination of these two drugs in 2012 to treat obesity. The drugs are to be used in combination with a reduced-calorie diet and exercise program in individuals with an initial body mass index (BMI) over 30 kg/m2 or those with a BMI of over 27 in combination with at least one obesity-related comorbidity. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, toxicity, and monitoring, of topiramate/phentermine so providers can direct patient therapy where they are indicated as part of the interprofessional team.

Target Audience

This activity has been designed to meet the educational needs of dieticians.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Describe the mechanisms of action of topiramate and phentermine.
  • Outline the indications for initiating topiramate/phentermine therapy in a weight loss regimen.
  • Review the adverse events profile for topiramate/phentermine combination therapy.
  • Summarize interprofessional team strategies for improving care coordination and communication to properly use topiramate/phentermine combination therapy to improve patient outcomes as part of a weight-loss regimen.

Author(s) / Contributors Disclosure of Conflicts of Interest

Hover over the contributor names to see details and disclosures of any financial relationships they have with commercial interests related to the content of this continuing education activity. All of the relevant financial relationships listed for these individuals have been mitigated.

COMMERCIAL SUPPORT: This activity has received NO commercial support.

Continuing Education Accreditation Information


 

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare. This activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare, and StatPearls Publishing, LLC.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and StatPearls Publishing, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Dieticians AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.25 CPEU

 


Cancellation Policy: Cancellations must be received in writing and a money-back guarantee is provided if not completely satisfied.

  • StatPearls and AKH reserve the right to cancel any course due to unforeseen circumstances. StatPearls and AKH will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

  • StatPearls and AKH are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

  • Computer Requirements:  Internet Access
  • E-mail Address

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the required accreditation information:  Target audience, learning objectives, and disclosure information.
  3. Complete the entire self-study activity.
  4. Complete the post-test assessments.
  5. Successfully pass the post-test with a minimum score of 100%.
  6. Complete the evaluation form.
  7. Obtain a certificate.

StatPearls and AKH adhere to provider standards regarding commercial support of continuing education. It is the policy of StatPearls and AKH that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

  • If you have concerns regarding the CE system, please contact support@statpearls.com, or call 727-289-9796.
  • If you have concerns regarding CE, please contact service@akhcme.com or call AKH 877-AKH-CME4.

Conflict of Interest Disclosure Policy:
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use:
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer:
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

 

Media Usage Rights

The contributors and editors of StatPearls have attested that all associated media (images and video) have been legally cleared for use with this activity.  All copyrights are reserved.

    Reviews

    Rana M. on 2/26/2021

    Ashley T. on 9/11/2021

    Lauren C. on 9/12/2021

    Molly D. on 2/21/2022

    Darren T. on 4/5/2022

    Lori N. on 4/16/2022

    Elina R. on 4/20/2022

    Janet M. on 5/4/2022

    Jesus m. on 5/11/2022

    Lacey S. on 5/22/2022

    Unlimited Dietitian CPEU

    Stay up to date on the latest medical knowledge with 103 CPEU activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 133.75 hours of CPEU.

    1 Year Unlimited Dietitian CPEU

    Access to all the Unlimited Dietitian CPEU activities.

    $49 per 1 year per user